Accelerate Enterprise Value over EBITDA from 2010 to 2024
| AXDX Stock | USD 0.77 0.03 4.05% |
Enterprise Value Over EBITDA | First Reported 2010-12-31 | Previous Quarter (1.50) | Current Value (1.57) | Quarterly Volatility 10.71222044 |
Check Accelerate Diagnostics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Accelerate main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.4 M, Interest Expense of 8.1 M or Selling General Administrative of 35.9 M, as well as many exotic indicators such as Price To Sales Ratio of 3.85, Dividend Yield of 0.0011 or Days Sales Outstanding of 75.39. Accelerate financial statements analysis is a perfect complement when working with Accelerate Diagnostics Valuation or Volatility modules.
Accelerate | Enterprise Value over EBITDA |
About Accelerate Diagnostics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Accelerate Diagnostics income statement, its balance sheet, and the statement of cash flows. Accelerate Diagnostics investors use historical funamental indicators, such as Accelerate Diagnostics's Enterprise Value over EBITDA, to determine how well the company is positioned to perform in the future. Although Accelerate Diagnostics investors may use each financial statement separately, they are all related. The changes in Accelerate Diagnostics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Accelerate Diagnostics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Accelerate Diagnostics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Accelerate Diagnostics. Please read more on our technical analysis and fundamental analysis pages.
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona. Accelerate Diagnosti operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 220 people.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Accelerate Diagnostics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Accelerate Diagnostics' short interest history, or implied volatility extrapolated from Accelerate Diagnostics options trading.
Pair Trading with Accelerate Diagnostics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Accelerate Diagnostics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Accelerate Diagnostics will appreciate offsetting losses from the drop in the long position's value.Moving against Accelerate Stock
| 0.7 | DNTH | Dianthus Therapeutics Symbol Change | PairCorr |
| 0.67 | VCEL | Vericel Corp Ord Downward Rally | PairCorr |
| 0.65 | VERA | Vera Therapeutics Financial Report 9th of May 2024 | PairCorr |
| 0.55 | EQ | Equillium Financial Report 9th of May 2024 | PairCorr |
| 0.48 | A | Agilent Technologies Financial Report 28th of May 2024 | PairCorr |
The ability to find closely correlated positions to Accelerate Diagnostics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Accelerate Diagnostics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Accelerate Diagnostics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Accelerate Diagnostics to buy it.
The correlation of Accelerate Diagnostics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Accelerate Diagnostics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Accelerate Diagnostics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Accelerate Diagnostics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Accelerate Diagnostics Correlation against competitors. For more information on how to buy Accelerate Stock please use our How to Invest in Accelerate Diagnostics guide.Note that the Accelerate Diagnostics information on this page should be used as a complementary analysis to other Accelerate Diagnostics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Complementary Tools for Accelerate Stock analysis
When running Accelerate Diagnostics' price analysis, check to measure Accelerate Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accelerate Diagnostics is operating at the current time. Most of Accelerate Diagnostics' value examination focuses on studying past and present price action to predict the probability of Accelerate Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Accelerate Diagnostics' price. Additionally, you may evaluate how the addition of Accelerate Diagnostics to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |
Is Accelerate Diagnostics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Accelerate Diagnostics. If investors know Accelerate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Accelerate Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.94) | Revenue Per Share 0.966 | Quarterly Revenue Growth 0.019 | Return On Assets (0.70) |
The market value of Accelerate Diagnostics is measured differently than its book value, which is the value of Accelerate that is recorded on the company's balance sheet. Investors also form their own opinion of Accelerate Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Accelerate Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Accelerate Diagnostics' market value can be influenced by many factors that don't directly affect Accelerate Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Accelerate Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Accelerate Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Accelerate Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.